Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM-CHOC-PEN + Radiation in CNS Cancer
NCT03371004Phase 1Completed
- Sponsor
- DEKK-TEC, Inc.
- Start
- Feb 2016
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mipicoledine in central nervous system cancer, sponsored by DEKK-TEC, Inc. Primary endpoint: Number of participants with treatment-related adverse events at 1 year. Started Feb 2016; status: completed.
02
Drugs
mipicoledine
03
Conditions
central nervous system cancer
Beyond the preview
Go deeper on NCT03371004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371004.